NCT06149182

Brief Summary

Functional somatic syndromes (e.g. irritable bowel syndrome, fibromyalgia) and medically unexplained symptoms (e.g. chronic primary pain) are very common in primary care. These patients make 14 times more doctor visits than the general population, but describe themselves as less satisfied with the care they receive. Although Region Stockholm in Sweden recently developed care flows based on 'step up' care for the most common patient groups in primary care, patients with functional or medically unexplained symptoms are not mentioned. Short-term psychodynamic therapies such as Emotional Awareness and Expression Therapy (EAET) and Intensive Short Term Psychodynamic Therapy (ISTDP) have recently been evaluated in three systematic reviews and show good results for patients with medically unexplained symptoms. Short-term psychodynamic therapy considers that good treatment outcomes for patients with functional somatic syndromes can be achieved by increasing awareness of emotions and teaching patients to better experience, express and regulate emotions. In several randomized studies, short-term psychodynamic therapy has shown good effects even compared to other treatments, including cognitive behavioral therapy (CBT). The overall purpose of this research project is to to evaluate psychodynamic emotion-focused interventions (EAET and ISTDP) for patients with medically unexplained symptoms and high health care consumption. The project includes several studies that will clarify effects and contribute to information on how care flows in primary care for the patient group can be created. The research question for this specific study is: Can a therapeutic interview (so-called "EAET life-stress interview") focusing on emotional factors in comparison to a psychiatric interview (so-called "basic assessment") contribute to increased interest in psychological treatment and reduction of physical and psychiatric symptoms in patients with medically unexplained symptoms with relatively high health care consumption? Does the order of interview interventions matter?

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
189

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Oct 2023

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 9, 2023

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

November 20, 2023

Completed
8 days until next milestone

First Posted

Study publicly available on registry

November 28, 2023

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2024

Completed
1.6 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2025

Completed
Last Updated

April 17, 2024

Status Verified

April 1, 2024

Enrollment Period

8 months

First QC Date

November 20, 2023

Last Update Submit

April 16, 2024

Conditions

Keywords

Functional somatic disorderSomatic symptom disorderlife stress interviewemotional awareness and expression therapyintensive short term psychodynamic therapyrandomized controlled trial

Outcome Measures

Primary Outcomes (2)

  • Numeric Rating Scales according to EURONET-SOMA

    Visual analogue scale 0-10 for symptom intensity and symptom interference. Higher scores indicates worse symptom/functioning.

    Change from pre to follow up (6 weeks after interview)

  • PHQ-15

    Ratings 0-2 on how troublesome somatic symptoms are experienced. Higher scores indicates worse symptom/functioning.

    Change from pre to follow up (6 weeks after interview)

Secondary Outcomes (8)

  • Numeric Rating Scales according to EURONET-SOMA

    Change from pre to post (within 1 week after interview)

  • PHQ-15

    Change from pre to post (within 1 week after interview)

  • PHQ-9

    Change from pre to post (within 1 week after interview) and follow up (6 weeks after interview)

  • GAD-7

    Change from pre to post (within 1 week after interview) and follow up (6 weeks after interview)

  • PCL-5

    Change from pre to post (within 1 week after interview) and follow up (6 weeks after interview)

  • +3 more secondary outcomes

Study Arms (2)

Life stress interview/therapeutic interview

EXPERIMENTAL

Revised "Life stress interview" according to protocol from emotional awareness and expression therapy

Behavioral: Life stress interview according to EAET

Psychiatric interview

ACTIVE COMPARATOR

Psychiatric interview (M.I.N.I. etc) according to "Region stockholm - basutredning"

Behavioral: Psychiatric interview according to "region stockholm - basutredning"

Interventions

This interview has the aim to jointly explore potential emotional factors contributing to patients functional somatic symptoms. While exploring this, it has the aim to not only describe such potential patterns but also emotionally process them.

Life stress interview/therapeutic interview

This interview has the aim to gain enough information to diagnose some of the main psychiatric disorders

Psychiatric interview

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • The research subject certifies that he/she has undergone medical assessment for his/her physical symptoms.
  • The subject must have visited a physician at least three times in the last year.
  • The subject rates either moderate distress from bodily symptoms in the PHQ-15 (over 10 points) or severe distress from a single bodily symptom (at least 2 points for this symptom).
  • The research participants expresses interest in investigating whether emotional factors such as stress may contribute to symptoms.
  • Research subjects either affirm the presence of emotionally difficult life events (affirm at least 1 such event in the ACE-10 or reach the proposed cut-off point of 21p in the PCL-5).
  • Drugs used should have been stable for at least 1 month.

You may not qualify if:

  • Research subjects suffer from ongoing substance abuse (alcohol or drugs) or are deemed to have serious mental illness (psychotic illness, suicidal ideation, antisocial personality disorder etc).
  • The research subjects have ongoing medication of a clearly addictive and sedative nature (e.g. benzodiazipines).
  • The research subject participates in other psychological treatment focusing on physical symptoms. However, other psychological treatment is allowed where the support therapy does not take place more often than once a month.
  • The research subject does not master the Swedish language sufficiently to be able to assimilate written material in Swedish.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Stockholm University

Stockholm, 10691, Sweden

Location

Study Officials

  • Peter Lilliengren, PhD

    Stockholm University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Researcher, Med.dr

Study Record Dates

First Submitted

November 20, 2023

First Posted

November 28, 2023

Study Start

October 9, 2023

Primary Completion

June 1, 2024

Study Completion

December 31, 2025

Last Updated

April 17, 2024

Record last verified: 2024-04

Locations